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Phospholipase Cε (PLCε) is a multifunctional enzyme
implicated in cardiovascular, pancreatic, and inflam-
matory functions. Here we show that conditional
deletion of PLCε inmouse cardiacmyocytes protects
from stress-induced pathological hypertrophy. PLCε
small interfering RNA (siRNA) in ventricular myocytes
decreases endothelin-1 (ET-1)-dependent elevation
of nuclear calcium and activation of nuclear protein
kinase D (PKD). PLCε scaffolded to muscle-specific
A kinase-anchoring protein (mAKAP), along with
PKCε and PKD, localizes these components at or
near the nuclear envelope, and this complex is
required for nuclear PKD activation. Phosphatidyli-
nositol 4-phosphate (PI4P) is identified as a perinu-
clear substrate in the Golgi apparatus for mAKAP-
scaffolded PLCε. We conclude that perinuclear
PLCε, scaffolded to mAKAP in cardiac myocytes,
responds to hypertrophic stimuli to generate diacyl-
glycerol (DAG) from PI4P in the Golgi apparatus, in
close proximity to the nuclear envelope, to regulate
activation of nuclear PKD and hypertrophic signaling
pathways.
INTRODUCTION
Heart failure is amajor global health problem and a leading cause
of mortality. In response to high blood pressure or other cardiac
stress, the adult heart remodels and enlarges in what is thought
to be an initial compensatory mechanism but that is maladaptive
in the long term and leads to cardiac decompensation and heart
failure. One major feature of cardiac remodeling is hypertrophic
growth of cardiac myocytes, driven in part by increased levels of
neurohumoral agonists such as norepinephrine and endothelin-1216 Cell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc.(ET-1), acting on G protein-coupled receptors (GPCRs) in
cardiac myocytes (Rockman et al., 2002).
Many hypertrophic agonists couple to activation of phos-
phoinositide-specific phospholipase C (PLC) to stimulate phos-
phatidylinositol 4,5-bisphosphate (PIP2) hydrolysis and produce
inositol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG), a key
reaction involved in mediating cardiomyocyte hypertrophy. Gaq,
a GTP-binding protein that directly activates PLC, is a major
participant in the hypertrophic process in mice (D’Angelo et al.,
1997; Dorn and Brown, 1999), and a splice variant of PLCb,
PLCb1b, is required for cardiomyocyte hypertrophy in vitro
driven by a-adrenergic receptor activation (Filtz et al., 2009;
Grubb et al., 2011).
A novel isoform of PLC, phospholipase Cε (PLCε), is down-
stream of both GPCRs and receptor tyrosine kinases by virtue
of its ability to be regulated by small GTPases, including Ras,
Rho, andRap, andbyheterotrimericGproteinbg subunits (Kelley
et al., 2001; Smrcka et al., 2012). We recently demonstrated that
hypertrophy of neonatal rat ventricular myocytes (NRVMs) driven
by ET-1, norepinephrine, or isoproterenol (Iso) was inhibited by
small interfering RNA (siRNA)-mediated knockdown of PLCε
(Zhang et al., 2011). Furthermore, it was shown that PLCε scaf-
folds to muscle-specific A kinase-anchoring protein (mAKAP)
at the nuclear envelope (NE), and disruption of this scaffolding
interaction prevents development of agonist-induced hyper-
trophy (Zhang et al., 2011). This suggests that PLCε generates
second messengers at the NE that are required for hypertrophy.
Canonical GPCR-mediated PIP2 hydrolysis by PLC occurs at
the plasma membrane (PM), where PIP2 is preferentially en-
riched. PIP2 is not readily detectable in intracellular organelle
membranes, and PI-dependent signaling processes in intracel-
lular membranes have not been well characterized. A phosphoi-
nositide cycle involving PIP2 hydrolysis is present in the nuclear
matrix (Divecha et al., 1993; Keune et al., 2011; Ramazzotti et al.,
2011). Turnover of nuclear PIP2 is not subject to regulation
by GPCRs, despite the presence of PLCb in the nucleus of
some cells, but IGF-1 has been shown to stimulate nuclear
PIP2 hydrolysis (Cocco et al., 1989; Divecha et al., 1991). Surpris-
ingly, nuclear PIP2 is not associated with NE membranes but
rather is in a poorly defined detergent-resistant structure in the
matrix (Keune et al., 2011). With no apparent PIP2 substrate at
the NE, a role for a PLC-hydrolytic activity associated with the
NE is not obvious, although it is theoretically possible that an
NE-scaffolded PLC could gain access to nuclear PIP2. Phospha-
tidylinositol 4-phosphate (PI4P) is an alternate substrate for puri-
fied PLC in vitro that is found in intracellular membranes, but
PI4P has not been shown to be a native physiological substrate
for PLC in cells. PI4P has been thought of primarily as a precursor
for replenishment of PI4,5P2 during active receptor-stimulated
PIP2 hydrolysis, but recent studies indicate that PI4P itself plays
other important roles in cell function (Hammond et al., 2012).
One of the key signaling events that leads to expression of
hypertrophic genes is phosphorylation of histone deacetylase
(HDAC5) and subsequent binding of phosphorylated HDAC to
14-3-3 proteins in the cytoplasm (Frey and Olson, 2003). Two
key kinases that phosphorylate HDAC at the nucleus are calcium
calmodulin-dependent protein kinase II (CamKII) and protein
kinase D (PKD) (Frey and Olson, 2003; McKinsey, 2007). CamKII
is regulated by calcium, and PKD is regulated by DAG and phos-
phorylation by protein kinase C (PKC) (Rozengurt, 2011; Stein-
berg, 2012), suggesting that Ca2+ and DAG levels need to be
elevated locally at the nucleus to maintain their activities. How
plasma-membrane GPCR-generated signals regulate these
nuclear proteins has not been carefully examined. It has been
generally assumed that IP3 generated as a result of PM PLCb
activiation can diffuse through the cytoplasm to NE, where IP3
receptors are enriched in cardiac myocytes to release a local
pool of Ca2+ (Higazi et al., 2009; Wu et al., 2006). DAG, on the
other hand, is diffusible within membranes but not between
membranes, so how PKD is activated at the nucleus is unclear.
There is evidence that PKD can be activated at the PM and
subsequently diffuse to the nucleus (Bossuyt et al., 2011), but
whether PM signals are sufficient for this process has not been
examined.
To determine the mechanistic role of PLCε in cardiac function
and failure, we deleted PLCε specifically in cardiac myocytes in
mice after development and examined the subcellular scaffolded
signals generated in cardiac myocytes by PLCε. We show that
mice with cardiac myocyte-specific deletion of PLCε are pro-
tected from pressure-overload-induced hypertrophy, clearly
identifying a gene critical for the development of heart failure.
Further, we define a role of nuclear-scaffolded PLCε in regulating
signaling proteins that drive hypertrophy. Notably, we identify
PI4P in the perinuclear Golgi apparatus as the key substrate
for PLCε at the NE for generation of local DAG and subsequent
nuclear PKD activation.
RESULTS
Cardiac-Specific Deletion of PLCε in PLCεflox/flox
a-MHC-MerCreMer Mice
Our recent results in NRVMs show that siRNA-based depletion
of PLCε prevents agonist-induced hypertrophy (Zhang et al.,
2011). This contrasts with our previous work demonstrating
that global knockout of PLCε exacerbates hypertrophy inresponse to isoproterenol infusion (Wang et al., 2005). To
clarify the role of PLCε in cardiac function and failure, we deleted
PLCε specifically in cardiac myocytes in mice after develop-
ment (Figure 1A and Experimental Procedures). PLCεflox/flox
mice (PLCεflox/flox Cre) were bred with a-MHC-MerCreMer
(a-MHC-MCM) mice to generate PLCεflox/flox Tg(a-MHC-MCM),
(PLCεflox/flox Cre+) mice (Figure 1A) (Sohal et al., 2001). After
1 month of postnatal development, mice from both genotypes
were given three daily injections of 40mg/kg bodyweight tamox-
ifen intraperitoneally (i.p.). PLCε messenger RNA (mRNA) was
decreased by 80% in myocytes isolated from PLCεflox/flox Cre+
mice compared to either PLCεflox/flox Cre or PLCε wild-type
(WT) mice (Figure 1B). PLCε protein was significantly reduced
(>70%) in myocytes isolated from PLCεflox/flox Cre+ mice relative
to PLCεflox/flox Cre mice, whereas in lung, the level of PLCε
protein was unchanged (Figure 1C). PLCε deletion in PLCεflox/flox
Cre+mice had no significant effect on ejection fraction, fractional
shortening, ventricular-wall dimensions, or left ventricular (LV)
mass in the absence of stress (Figure 1E). Previous data from
global PLCε/ mice showed no changes in levels of other
PLCb1, PLCb3, PLCg1, or PLCd3 compared to PLCε+/+ mice
(Wang et al., 2005).
Cardiac-Specific Deletion of PLCε Inhibits Development
of Hypertrophy after Transverse Aortic Constriction
After 4 weeks of transverse aortic constriction (TAC), PLCεflox/flox
Cre mice had increased heart size, LV and right ventricular
(RV) wall thickness, and interstitial fibrosis (Figure 1D, cre).
These morphological changes were significantly inhibited in
the PLCεflox/flox Cre+ animals (Figure 1D, cre+). PLCεflox/flox
Cre mice developed a severe decrement in heart function
with a drastic decrease in ejection fraction and fractional short-
ening, had a significant increase in heart weight (HW) to tibia
length (TL), and showed large increases in hypertrophic gene
expression (Figure 1E and Figures S1A andS1B available online).
In contrast, PLCεflox/flox Cre+ mice were significantly protected
from these hypertrophy-related changes (Figures 1E, S1A, and
S1B). These data indicate that cardiomyocyte PLCε plays a
role in mediating cardiac hypertrophy, supporting the mecha-
nistic data obtained in NRVMs.
Characterization of Signaling Pathways Associated with
PLCε Deletion in Cardiomyocytes
In the global PLCε knockout (KO) animal, CamKII phosphoryla-
tion was basally increased (see Figure S5 in Zhang et al.,
2011), but here in the cardiac-specific KO, there was no detect-
able increase in CamKII phosphorylation nor PKD phosphoryla-
tion under basal conditions (Figures 1F and S1C). TAC increased
phosphorylation of PKD at S916 and S744/748 in PLCεflox/flox
Cre relative to control (Ctl) animals. This phosphorylation is
significantly blunted in the PLCεflox/flox Cre+ animals (Figures 1F
and S1C). Similarly, CamKII phosphorylation is increased by
TAC in the PLCεflox/flox Cre mice and is significantly blunted in
the PLCεflox/flox Cre+ mice (Figures 1F and S1C). These two
kinases phosphorylate HDAC to cause translocation of HDAC
from the nucleus to the cytoplasm, leading to MEF-dependent
transcription of hypertrophic genes (Frey and Olson, 2003).
HDAC phosphorylation was also blunted in the PLCεflox/floxCell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc. 217
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Figure 1. Conditional Deletion of PLCε in
Cardiac Myocytes Prevents Development
of Cardiac Hypertrophy
(A) Domain Structure of PLCε and Strategy for
Conditional Deletion of PLCε. Exon 6 encodes the
first common exon of two PLCε splice variants at
the amino terminus of the CDC25 domain. Exon 6
was flanked by two LoxP sites as shown. Small
arrows indicate location of primers for genotyping,
and small bars indicate the location of Southern
blot probes.
(B) One-month-old PLCεfl/flCre+ and PLCεfl/flCre
mice were injected with 40 mg/kg of tamoxifen
once/day for 3 consecutive days. PLCεmRNAwas
measured by real-time quantitative PCR and
normalized to GAPDH levels.
(C) PLCε protein was immunoprecipitated and
analyzed by western blotting. GAPDH from the
lysates was immunoblotted as a loading control.
KO controls are from globally deleted PLCε/
mice shown for comparison.
(D) Anatomical view, histological HE-stained
sections, and trichome-stained (for fibrosis, blue)
sections from hearts from tamoxifen-treated
PLCεfl/fl mice with or without 4 weeks of TAC.
(E) Quantitation of heart weight to tibia length
(HW/TL), ANF/GAPDH mRNA levels by RT-PCR,
ejection fraction (by echocardiography), and frac-
tional shortening (by echocardiography) (± stan-
dard error of the mean [SEM]). Analyzed by
one-way ANOVA: 7 mice Cre, 11 mice Cre+,
*p < 0.05, **p < 0.01, ***p < 0.005.
(F) Western blots of PKD, phosphoPKD, CamKII,
phosphoCamKII, HDAC, phosphoHDAC, and
GAPDH from tamoxifen-injected mice with and
without TAC.
See also Figure S1.Cre+ compared to PLCεflox/flox Cre mice (Figures 1F and S1C).
Based on these data, we hypothesize that PLCεmay be involved
in regulation of PKD- and CAMKII-dependent phosphorylation of
HDAC in cardiac myocytes.
Gaq-Dependent Hypertrophy Requires mAKAP-Bound
PLCε
Gaq signaling has been shown to be a primary driver of hyper-
trophy both in NRVMs and in mice (D’Angelo et al., 1997; Knowl-
ton et al., 1993). To directly test the involvement of PLCε in Gaq-
dependent hypertrophy, adenovirus expressingGaq was used to
infect NRVMs along with an adenovirus expressing either PLCε
siRNA or a random siRNA Ctl sequence. As previously reported,
expression of Gaq caused an increase in NRVM cell area (Fig-
ure 2A) and atrial natriuretic factor (ANF) mRNA (Figure 2B) ex-
pression, relative to infection with Ctl lacZ- or yellow fluorescent218 Cell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc.protein (YFP)-expressing viruses. Deple-
tion of PLCε by siRNA completely in-
hibited the development of hypertrophy
by Gaq assessed by both of these
measures (Figures 2A and 2B).
To test whether mAKAP-PLCε scaf-
folding was important for Gaq-depen-dent hypertrophy, we coexpressed Gaq with the mAKAP-
spectrin repeat homology domain 1 (SR1) domain, documented
previously to disrupt mAKAP-PLCε interactions at the NE (Zhang
et al., 2011). Expression of the SR-1 domain almost completely
inhibited hypertrophy driven by Gaq (Figure 2C), indicating that
NE scaffolding of PLCε via mAKAP is important for Gaq-depen-
dent NRVM hypertrophy.
Scaffolding of PLCε, PKCε, and PKD to mAKAP
mAKAP is a large scaffoldingprotein localized to theNE in cardiac
myocytes, and it scaffolds to many partners, including PLCε
(Dodge-Kafka et al., 2005; Kapiloff et al., 2001; Zhang et al.,
2011). We have shown by biochemical fractionation that PLCε is
localized to the nuclear fraction of cardiac myocyte lysates along
with mAKAP (Zhang et al., 2011). Expression of PLCε fused to
mCherry was enriched at the periphery of the nucleus in NRVMs
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Figure 2. Gaq-Stimulated Hypertrophy in
NRVMs Is Blocked by PLCε siRNAorDisrup-
tion of NE Scaffolding via mAKAP
(A) NRVMs were transduced with 50 MOI of
adenovirus expressingWTGaq or LacZ. Cells were
cotransduced with either PLCε siRNA or control
scrambled siRNA (Ctl) adenovirus. After 48 hr, cells
were fixed, permeabilized, and stained for a-acti-
nin. Cell area was calculated from 200 cells each
treatment with NIH ImageJ and pooled from three
separate experiments in the right panel (± SEM).
(B) Same as (A), except ANF/GAPDH ratio was
determined by quantitative real-time PCR (± SEM).
(C) NRVMs were cotransduced with adenoviruses
expressing Gaq and mAKAP-SR domain. ANF/
GAPDH ratio was measured after 48 hr (± SEM).
All experiments were repeated three times and
were analyzed by one-way ANOVA, *p < 0.05;
***p < 0.005.(Figure3A), andsomePLCε is localized toendoplasmic reticulum/
sarcoplasmic reticulum (ER/SR)-like structures.
To identify other components in this complex that are
potentially involved in PLCε signaling, we immunoprecipitated
PLCε from mouse heart lysates and immunoblotted for key
potential upstream regulators and downstream targets. First
we looked for Epac1 association because Epac is upstream of
PLCε-dependent regulation of cardiac contractile function and
has been previously identified in mAKAP immunoprecipitates
(Dodge-Kafka et al., 2005; Oestreich et al., 2007, 2009). Both
PLCε and mAKAP immunoprecipitates contained Epac1 (Fig-
ure 3B). When PLCε was cotransfected into HEK293 cells with
Epac1, Epac1 was detected in PLCε immunoprecipitates (Fig-
ure S2A). Coexpression of mAKAP did not alter the efficiency
of the immunoprecipitation, suggesting that PLCε directly binds
to Epac1. To further characterize the interaction, purified GST-
Epac1 was tested for binding to purified PLCε. GST-Epac1
specifically bound to PLCε, confirming a direct interaction (Fig-
ure S2B). To determine whether interaction of Epac1 with PLCε
was required for association with AKAP in the heart, we com-
pared AKAP immunoprecipitates from PLCε/ and PLCε+/+
mouse heart lysates (Figure S2C). Epac1 was detectable in the
lysates from both genotypes, but the level of Epac1 was signifi-
cantly lower in immunoprecipitates from PLCε/mouse hearts,
suggesting that binding of Epac1 to PLCε contributes to scaf-
folding of Epac1 to mAKAP.
We had also previously shown that PLCε regulates phos-
phorylation of Ryr2 through a PKCε- and CamKII-dependent
mechanism during acute b-adrenergic receptor (bAR) activation
(Oestreich et al., 2009). We examined PLCε immunoprecipitatesCell 153, 216–22for the presence of Ryr2 and found Ryr2
immunoreactivity only in lysates from
hearts isolated from PLCε+/+ mice (Fig-
ure 3C). Ryr2 has been shown to bind to
mAKAP, so it is possible that this interac-
tion is indirect. When coexpressed in
HEK293 cells, Ryr2 weakly interacted
with PLCε in a manner that was not
affected by coexpression of mAKAP(data not shown). This suggests that mAKAP does not mediate
Ryr2 scaffolding to PLCε, but because the PLCε-Ryr2 interaction
is weaker in cotransfected cells than in heart lysates, another
protein is likely to participate in PLCε-Ryr2 scaffolding. Immuno-
depletion of heart lysates with mAKAP antiserum reduces, but
does not eliminate, Ryr2 immunoprecipitation with PLCε (Fig-
ure S2D). This indicates that a fraction of PLCε is scaffolded to
Ryr2 but is not associatedwithmAKAP, supporting the existence
of multiple pools of PLCε in cardiac myocytes.
Because PKCε and PKD are critical hypertrophic kinases that
we propose are downstream of PLCε, we examined their scaf-
folding to mAKAP and PLCε. We had previously shown that
PLCεmediates PKCε activation in adult cardiacmyocytes during
acute bAR stimulation (Oestreich et al., 2009). PLCε and mAKAP
immunoprecipitates from heart lysates contained both PKCε and
PKD immunoreactivity (Figures 3D and 3E). PLCε immunopre-
cipitates from hearts isolated from PLCε/mice did not contain
PKCε immunoreactivity confirming the specificity of the immuno-
precipitation. Together, these data indicate that many of the
signaling components required for PLCε action in cardiac myo-
cytes involved in either regulation of contraction or hypertrophy
are assembled into a signaling complex with mAKAP. More
importantly, these data show that the key hypertrophic regula-
tors, PKCε and PKD, are scaffolded with PLCε and mAKAP at
the NE, where they play key functional roles analyzed below.
mAKAP-Bound PLCε Is Involved in Nuclear PKD
Activation in NRVMs
To test the involvement of PLCε in ET-1-dependent PKD activa-
tion, PLCε was depleted in NRVMs using siRNA, and PKD S9167, March 28, 2013 ª2013 Elsevier Inc. 219
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Figure 3. PLCε Is in a Multicomponent Signaling Complex with
mAKAP, Epac, PKCε, PKD, and Ryr2 in the Heart
(A) perinuclear localization of PLCε in NRVMs. mCherry-tagged PLCε was
expressed in NRVMs (left panel) and costained with DAPI (right panel). The
boundaries of the cell are outlined with dashed lines.
(B) Epac coimmunoprecipitates with PLCε and mAKAP from heart lysates.
(C) Ryr2 immunoprecipitates with PLCε from heart lysates.
(D) PKCε immunoprecipitates with PLCε and mAKAP from heart lysates.
(E) PKD immunoprecipitates with PLCε and mAKAP from heart lysates.
PLCε/ mice were tested as a specificity control in (B), (C), and (D). See also
Figure S2.phosphorylation wasmeasured. PKD phosphorylation increases
after 10 min of ET-1 stimulation and declines thereafter but
remains active for at least 4 hr (Figure S3). ET-1 stimulation
of PKD phosphorylation in PLCε siRNA-treated NRVMs was
blunted compared to Ctl siRNA-treated cells at all times
measured. We more carefully examined inhibition by PLCε
depletion after stimulation with ET-1 and norepinephrine for
1 hr and ET-1 for 24 hr (Figure 4A). At both times, ET-1-depen-
dent PKD phosphorylation was inhibited in PLCε siRNA-treated
NRVMs by approximately 50%. This indicates that PLCε is
important for activation of PKD, but because inhibition of total
cellular PKD activation by PLCε depletion is partial, PLCε may
be regulating a specific subcellular pool of PKD.
To determine whether mAKAP-associated PLCε was involved
in PKD activation, PLCε-mAKAP interactions were disrupted
by expression of mAKAP-SR1 or PLCε-ras-association 1 (RA1)
domains (Zhang et al., 2011), and ET-1-stimulated phosphoryla-
tion of PKD at 1 hr and 24 hr was measured. Expression of either
PLCε-RA1 or mAKAP-SR1 domains inhibited ET-1-dependent
global PKD phosphorylation at 1 hr (30%) and 24 hr (70%) (Fig-
ure 4B). To determine whether PLCε is required for activation of220 Cell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc.the nuclear pool of PKD, NRVMs were transduced with an
adenovirus expressing a nuclear-targeted fluorescence reso-
nance energy transfer (FRET)-based reporter of PKD activity,
nuclear D kinase activity reporter (nDKAR) (Bossuyt et al.,
2011; Kunkel et al., 2007). Figure 4C is a YFP/ cyan fluorescent
protein (CFP) ratiometric image fromNRVMs expressing nDKAR,
with CFP excitation showing basal FRET in the nucleus as previ-
ously reported (Bossuyt et al., 2011). NRVMs were treated with
either vehicle or ET-1, and nuclear FRET was monitored over
time. ET-1 treatment causes a significant decrease in nuclear
FRET over the course of 20 min compared to vehicle Ctl (Figures
4D and 4E). In NRVMs treated with PLCε siRNA, the ET-1-
induced decrease in FRET was completely eliminated (Figures
4D and 4E). Expression of mAKAP-SR1 in NRVMs also com-
pletely inhibited the ET-1-dependent decrease in nDKAR FRET
(Figure 4F). This indicates that ET-1 activates nuclear PKD, and
that this nuclear PKD activation requires mAKAP-scaffolded
perinuclear PLCε.
PLCε Is Important for Localized Nuclear Calcium Signals
ET-1 induces calcium increases in the nuclei of cardiac ventric-
ular myocytes; this process is dependent on IP3 presumably
binding to type II IP3 receptors localized at the NE (Higazi
et al., 2009; Wu et al., 2006). Several reports indicate that the
myocyte nuclear Ca2+ release via IP3 receptors canmediate car-
diomyocyte hypertrophy (Arantes et al., 2012; Higazi et al., 2009;
Nakayama et al., 2010). To monitor changes in nuclear calcium
levels, we utilized Fura-2-loaded NRVMs and specifically moni-
tored the nuclear regions of the cells by ratio imaging epifluores-
cence microscopy (Figure 5A). NRVMs were pretreated with
nifedipine (L-type Ca2+ channel blocker) and mibefradil (L- and
T-type Ca2+ channel blocker) to block Ca2+ entry and Ca2+
release associated with myocyte excitation contraction (Higazi
et al., 2009). ET-1 stimulated an increase in nuclear [Ca2+] that
was inhibited by PLCε siRNA treatment (Figure 5A). Expression
of the RA domain of PLCε to disrupt AKAP-dependent nuclear
scaffolding also inhibited nuclear Ca2+ release but only by
10%–20% (Figure 5A, middle right panel). This nuclear Ca2+
release is likely IP3 dependent, as previously reported (Higazi
et al., 2009), because it was not affected by blocking the other
major Ca2+-release channel, Ryr2, with ryanodine (Figure 5A,
right panel). To confirm that the ET-1-dependent Ca2+ increases
are localized to the nucleus, we used two-photon microscopy to
examine ET-1-dependent increases in nuclear Ca2+ signals in
NRVMs. Treatment with ET-1 results in a robust Ca2+ release
that is primarily restricted to the nucleus (Figure 5B; Movie S1),
as previously reported.
These data indicate that IP3 generated by PLCε-dependent
PIP2 hydrolysis contributes to nuclear Ca
2+ signals that may be
important for regulation of hypertrophy, but that PLCε scaffolded
at the NE is not a major participant in this release. This suggests
that PLCε localized elsewhere, possibly at the PM, contributes to
diffusible IP3 generation necessary for release of Ca
2+ at the NE.
Perinuclear PI4P Localization
To identify potential perinuclear substrates for PLCε, we utilized
specific fluorescent probes containing GFP fused to domains
that recognize specific phosphoinositides (Balla et al., 2009).
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Figure 4. PLCεRegulates Nuclear PKDActi-
vation
(A) NRVMs were infected with PLCε or control (Ctl)
siRNA, followed by treatment with 100 nM ET-1 or
10 mM norepinephrine (NE) for 1 hr and ET-1 for
24 hr and assessment of PKD phosphorylation
by western blotting, each repeated 3–4 times.
Statistically different from Ctl siRNA, **p < 0.01,
***p < 0.005.
(B) NRVMs were infected with either control YFP,
mAKAP-SR, or PLCε-RA expressing adenoviruses
to disrupt PLCε-mAKAP scaffolding, followed by
treatment with 100 nM ET-1 for 1 hr or 24 hr and
assessment of total PKD activation. Statistically
different from Ctl siRNA, ***p < 0.005.
(C) NRVMs were transduced with adenovirus-ex-
pressing nDKAR. The YFP to CFP ratio is shown as
a pseudocolor image to emphasize the high level
of FRET in the nucleus.
(D) A region in the nucleus fromNRVMs expressing
nDKAR FRETwas selected, and the YFP/CFP ratio
was followed for the indicated times after 100 nM
ET-1 addition in PLCε siRNA or Ctl siRNA adeno-
virus-treated NRVMs.
(E) Pooled data for the YFP/CFP ratio of nDKAR
analyzed 20min after addition of ET-1 (+) or vehicle
() from five independent experiments in PLCε
siRNA- or Ctl siRNA-expressing NRVMs (50–100
cells each condition); ***p < 0.005.
(F) NRVMs were cotransfected with plasmids ex-
pressing nDKAR andmAKAP-SR1 or control LacZ.
ET-1 (100 nM) was added at the indicated time.
Data are pooled from four independent cells
for each treatment from two separate NRVM
preparations.
All quantitative data are ± SEM. See also
Figure S3.
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Figure 5. PLCε Is Involved in Regulation of Nuclear Ca2+ Elevation
(A) NRVMswere loadedwith Fura-2, and the Fura-2 ratio in the nucleus wasmeasuredwith time after 200 nMET-1 addition in the presence of a 10 mMnifedepine/
2 mMmibefradil. Left panel is a representative trace from two individual cells. Middle left panel is the combined data frommultiple cells comparing Ctl siRNA- and
PLCε siRNA-treated NRVMs, ***p < 0.005. Middle right panel is the combined data from cells expressing either YFP or the YFP-RA domain to disrupt mAKAP
scaffolding. Both sets of data are from four independent experiments from cells isolated from four different NRVM preparations with >10 cells for each coverslip
and 3 coverslip averages for each NRVM preparation; *p < 0.05, calculated based on an average of 12 coverslip averages for each condition. Right panel shows
that the ET-1-dependent nuclear Ca2+ response is not blocked by Ryanodine, but the caffeine response is (this experiment was repeated with two separate sets
of NRVMs; data are representative of one experiment with 30 cells each condition). All data are ± SEM.
(B) Two-photon microscopy was used to measure nuclear Ca2+ levels in Fluo-4-loaded NRVMs. Cells were perfused with imaging buffer containing 10 mM
nifedepine and 1.8 mMmibefradil to block Ca2+ transients associated with voltage-dependent Ca2+ release followed by addition of 100 nMET-1. Individual panels
show the level of Fluo-4 fluorescence at the indicated times (seeMovie S1). The boxes in the first panel correspond to the areas shown in the traces shown on the
right.To localize PIP2, we transfected cells with reporters containing
GFP fused to the pleckstrin homology (PH) domain of PLCd or
the PIP2-binding domain of Tubby and examined the cells by
confocal fluorescence microscopy. Both of these constructs
bind to PIP2 specifically, but PLCd-PH also binds IP3. Transfec-
tion of GFP-Tubby (Figure 6A) or GFP-PLCd-PH (not shown) into
HEK293 cells revealed a prominent PM distribution of PIP2 with
some intracellular fluorescence but no obvious localization near
the NE (Figure 6A). Transfection of NRVMs with the same
constructs revealed a similar PM distribution of PIP2 (Figure 6A).
Thus PIP2 is not detectable at the NE in NRVMs and is likely not
available as a substrate for NE-scaffolded PLCε activity.
PI4P is also a substrate for PLCε and other mammalian PLC
isoforms in vitro, but its utilization as a substrate in cells
has not been demonstrated (Rhee et al., 1989; Seifert
et al., 2004; Smrcka et al., 1991). To determine the localization
of PI4P in NRVMs, cells were transfected with reporters contain-
ing GFP fused to the PH domains of either four-phosphate
adaptor protein (FAPP) or oxysterol-binding protein (OSBP).
These reporters selectively monitor PI4P subcellular localization
in living cells, but this binding is codependent on interaction with
the small GTPase ARF (Balla et al., 2005). Thus they readily
detect PI4P at intracellular membranes containing ARF. As previ-222 Cell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc.ously reported in other cultured cells, transfection of GFP-
FAPP-PH into HEK293 cells leads to prominent fluorescence
at asymmetrically localized structures that correspond to the
Golgi apparatus (Figure 6B, left panel). Surprisingly, and in
striking contrast to other cultured cells, both FAPP-PH-GFP
and OSBP-PH-GFP strongly show a ring of perinuclear fluores-
cence surrounding the nucleus in NRVMs (Figure 6B, middle
and right panels and Figure S4A). In some cells, other intracel-
lular structures resembling either Golgi or SR were labeled (Fig-
ure 6C, for example), but this was generally less prominent.
Treatment with Brefeldin A to inhibit ARF resulted in rapid deple-
tion of perinuclear FAPP-PH-GFP fluorescence (Figure 6C).
Perinuclear FAPP-PH-GFP fluorescence was also completely
disrupted by treatment with PI4-kinase inhibitor phenylarsine
oxide (PAO) (Figure 6D).
Brefeldin A is an agent used to disrupt the Golgi apparatus
through its ability to block Golgi-localized ARF. ARF and PI4P
are enriched in the Golgi in most cells and play important roles
in Golgi-membrane vesicle and lipid trafficking. This suggested
that the perinuclear PI4P may be in Golgi closely associated
with the outer surface of the nucleus. Treating cells with a
BODIPY-TR ceramide to fluorescently label the Golgi revealed
a perinuclear ring similar to what is observed with the PI4P
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Figure 6. PI4P Localizes to Perinuclear Golgi Surrounding the NE in
Cardiac Myocytes
(A) Detection of PI4,5P2 localization in NRVMs. Left panel: HEK293 cells
transfected with Tubby-GFP and stained with DAPI; middle: NRVMs trans-
fected with Tubby-GFP; right: NRVMs transfected with PLCd-PH-GFP and
analyzed by confocal microscopy.
(B) Detection of PI4P at the NE. The indicated cell types were transfected
with either OSBP-PH-GFP or FAPP-PH-GFP and analyzed by confocal
microscopy.
(C) Inhibition of ARF eliminates perinuclear staining with FAPP-PH-GFP.
NRVMs transfected with FAPP-PH-GFP were treated with 1 mg/ml Brefeldin A,
and GFP fluorescence monitored with time. Cells treated with vehicle are
shown in the bottom panels and indicate a lack of photobleaching in these
experiments.
(D) Inhibition of PI4kinase with PAO depletes perinuclear fluorescence
associated with FAPP-PH-GFP. NRVMs transfected with FAPP-PH-GFP
were treated with 10 mM PAO, and fluorescence analyzed by confocal
microscopy.
All experiments were repeated a minimum of three times. See also Figure S4.reporters (Figure S4B). Indeed, previous studies have shown that
the Golgi surrounds the nucleus in myocytes and is intimately
associated with the NE at a constant distance of 100–200 nm
(Kronebusch and Singer, 1987; Tassin et al., 1985). Together
these data indicate that PI4P is localized to the Golgi apparatus,
in close proximity to the NE, where it could be accessed by
mAKAP-scaffolded PLCε.
PLCε Activation at the NE Leads to PI4P Depletion and
DAG Generation
To assess whether perinuclear PI4P is a substrate for PLCε, we
treated cells with a specific activator of Epac, 8-(4-chlorophe-
nylthio)-20-O-methyl-cAMP (cpTOME). Epac-dependent Rap
activation stimulates PLCε but no other PLC isoforms, and
Epac is scaffolded at the NE with PLCε and mAKAP. Thus,
PLCε in this NE-signaling complex can be activated selectively
with cpTOME. Treatment of NRVMs with cpTOME for 1 hr
caused a significant depletion of perinuclear Golgi FAPP-PH-
GFP fluorescence (Figure 7A). Selected regions of perinuclear
FAPP fluorescence were monitored in single live cells over
time after addition of vehicle Ctl, cpTOME, or ET-1 (Figure 7B;
Movie S2). Both cpTOME and ET-1 treatment enhanced the
rate of depletion of FAPP-PH-GFP fluorescence compared to
vehicle Ctl. ET-1-dependent decreases in PI4P were blocked
by preincubation with the ET-1a receptor antagonist BQ-123
(Figure 7B). We used a PI4P strip mass assay to measure total
PI4P levels in NRVMs after vehicle or cpTOME treatment (Dowler
et al., 2002). Treatment with cpTOME led to a significant
decrease in cellular PI4P mass compared to vehicle-treated
NRVMs (Figure 7C). Similar studies examining PIP2 at the PM
indicate that cpTOME does not stimulate PM-dependent PIP2
depletion (Figure S5A). To show that ET-1-dependent perinu-
clear PI4P depletion was dependent on mAKAP-scaffolded
PLCε, cells were cotransfected with GFP-FAPP-PH and either
mAKAP-SR1 or Ctl vector (Figure 7D). In cells transfected with
mAKAP-SR1, ET-1-dependent depletion of PI4P was blocked.
Additionally, as shown in Figure 7E, depletion of PLCε with
PLCε-siRNA completely eliminated cpTOME-dependent deple-
tion of perinuclear PI4P. These data strongly indicate that
mAKAP-scaffolded PLCε is directly involved in perinuclear
PI4P depletion consistent with its activity as a perinuclear
enzyme that can hydrolyze PI4P (Figure S5B) to produce DAG.
One consideration is that although PIP2 is undetectable in the
perinuclear Golgi in cardiac myocytes (Figure 6A), there could
be a very low level of PIP2 that is the direct substrate for perinu-
clear PLCε. In this scenario, PI4P might be indirectly depleted to
replace the hydrolyzed PIP2 pool. To test this, a PI5 phospha-
tase was targeted to the Golgi or the PM with a rapamycin-
recruitable type IV PI5P ptase domain fused to FKBP12 (Varnai
et al., 2006). This PI5 ptase cleaves the 5-phosphate from
PI4,5P2, effectively depleting PIP2. Figure S6A shows that tar-
geting of the PI5 ptase to the PM eliminates GFP-Tubby labeling
of the PM, indicating that the targeted PI5 ptase depletes PM
PIP2. Targeting of the PI5 ptase to the Golgi with rapamycin
does not alter PI4P levels (Figures S6B and S6C, black
squares). Treatment with cpTOME depletes PI4P at the perinu-
clear Golgi at the same rate in the presence or absence of
rapamycin-dependent targeting of the PI5P ptase to the GolgiCell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc. 223
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Figure 7. Perinuclear PI4P Is a Substrate for mAKAP-Scaffolded PLCε, Stimulated by either Epac or ET-1 Receptors
(A) NRVMs transfected with FAPP-PH-GFP were analyzed by live-cell confocal microscopy before and after treatment with 10 mM cpTOME for 1 hr (see also
Movie S2).
(B) Individual regions of GFP fluorescence in NRVMs transfected with FAPP-PH-GFP were monitored with confocal microscopy and followed with time after
treatment with vehicle, 10 mM cpTOME, 50 nM ET-1, or 50 nM ET-1+ 100 nM BQ-123 (top panels are representative traces). Data were pooled from four
experiments at 0 and 50 min for quantitation and statistics (bottom panels).
(C) NRVMs were treated with vehicle or 10 mM cpTOME for 50 min followed by extraction of PI4P and assay using a PI4P protein-lipid overlay assay according to
the manufacturer’s instructions. Data from three separate experiments are quantitated in the bottom panel and analyzed by a Student’s t test.
(D) NRVMs were cotransfected with FAPP-PH-GFP and either mAKAP-SR1 or control plasmid. Perinuclear GFP fluorescence was monitored as in (B). ET-1
experiments in (B) and (D) were done in parallel so the ET-1 alone representative traces are the same in both panels. Top panel is a representative trace, and
bottom panel is pooled data from three experiments analyzed by one-way ANOVA.
(E) NRVMs were transfected with FAPP-PH-GFP and transduced with viruses expressing PLCε siRNA or random control siRNA, and perinuclear GFP fluores-
cence was monitored as in (B) and (D). Data are pooled from five independent experiments each.
(F) NRVMs were transfected with YFP-C1b-Y123W to detect DAG localization. Left panel shows localization of YFP-C1b-Y123W by confocal microscopy. Right
panel: NRVMs transfected with YFP-C1b-Y123Wwere stimulated with 10 mM cpTOME, and perinuclear regions and cytoplasm were imaged over time. The ratio
of perinuclear fluorescence (Fpn) to the cytoplasmic fluorescence (Fc) was calculated and normalized to the starting Fpn/Fc before cpTOME addition. Data are
pooled from four independent experiments; Fpn/Fc at 9–12 min were individually compared with Fpn/Fc at 0 min with a one-way ANOVA.
(G) Golgi-specific depletion of PI4P blocks ET-1-dependent nuclear PKD activation. Left panel: Cells were transduced with GFP-tagged, Golgi-targeted Sac-1
and imaged by confocal microscopy. Right panel: Cells were cotransfected with plasmids expressing nDKAR and Golgi-targeted Flag-tagged Sac-1 plasmids,
and nDKAR FRET was monitored as in Figures 4D and 4F. Fifty nanomolar ET-1 was added at the indicated time.
Data were pooled from four independent cells for each treatment from two separate NRVM preparations. All data are ± SEM. See also Figures S5, S6, and S7 and
Movie S2.(Figure S6C). This indicates that perinuclear Golgi PI4P deple-
tion is not dependent on PIP2 hydrolysis in the Golgi, further
supporting the idea that the direct substrate for perinuclear
PLCε is PI4P.
To test for production of perinuclear DAG, cells were trans-
fected with a DAG-binding domain (C1b domain of PKCbII with
a Y123Wmutation) that is fused to YFP (YFP-C1b-Y123W), binds
with high affinity to DAG, and translocates to membranes where
DAG is produced (Kunkel and Newton, 2010). In resting cells,
there was basal association of the reporter with perinuclear224 Cell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc.and other cellular membranes (Figure 7F). This could be due to
basal turnover of lipids in the Golgi in the presence of serum,
or the very high affinity of this reporter for DAG could stabilize
a turning-over DAG pool. Nevertheless, treatment with cpTOME
increased the association of a DAG reporter with the perinuclear
region of the cell. The increase was small (10% increase) but
reproducible and consistent with what has been previously
observed for this DAG reporter in the Golgi in other cell types
(Kunkel and Newton, 2010). Thus DAG is generated in close
proximity to the NE by stimulation of PLCε.
To test whether PI4P is required for nuclear PKD activation,
PI4Pwas depleted in NRVMs using PAO (as shown in Figure 6D),
and ET-1-dependent nuclear PKD activity was monitored using
nDKAR (Figure S7). PAO depletes cellular PI4P in cells without
depleting the PIP2 pools necessary for conventional PLC-medi-
ated PIP2 hydrolysis (Hammond et al., 2012). By examining the
effect of PAO treatment on GFP-Tubby fluorescence, we also
found that PAO does not deplete NRVM PIP2 (data not shown).
PAO treatment completely eliminated ET-1-dependent nuclear
PKD activation, indicating that PI4P is a required substrate for
nuclear PKD activation, which supports the idea that Golgi
PI4P is required for nuclear PKD activation.
To more directly show that Golgi-localized PI4P is required for
nuclear PKD activation, we transfected cells with a variant of the
PI4P-specific phosphatase, Sac1, with a mutation leading to
specific localization in the Golgi (Sac1-K2A) (Blagoveshchen-
skaya et al., 2008; Rohde et al., 2003). In the left panel of Fig-
ure 7G is an NRVM transfected with GFP-Sac1-K2a, showing
perinuclear Golgi localization of Sac1-K2A. Sac1-K2A transfec-
tion completely eliminated the ET-1-dependent decrease in
nDKAR FRET, demonstrating that PI4P in the Golgi is required
for nuclear PKD activation (Figure 7G, right panel). We conclude
that mAKAP-scaffolded PLCε generates DAG from PI4P in close
proximity to the NE required for nuclear PKD activation.
DISCUSSION
We previously demonstrated that PLCε integrates multiple
hypertrophic stimuli in neonatal rat ventricular myocytes (Zhang
et al., 2011). Here we demonstrate that cardiac-specific deletion
of PLCε after 1 month of development significantly inhibits
cardiac hypertrophy development. This strongly suggests that
PLCε signaling in the cardiac myocyte is important for hyper-
trophy development, and that the neonatal myocyte analysis of
PLCε function is largely relevant to whole-heart function in an
animal.
Our previously published data established that both phos-
phoinositide hydrolysis by PLCε and NE scaffolding of PLCε
via mAKAP are required for PLCε-dependent hypertrophy in
NRVMs (Zhang et al., 2011). This suggested that PLCε must be
generating IP3, DAG, or both at the NE to drive hypertrophic
signaling cascades at the nucleus. IP3 generated at the PM is
diffusible, so agonist-dependent nuclear Ca2+ release could be
controlled by IP3 generated from PM PIP2 pools. DAG, on the
other hand, is a membrane-bound lipid, not freely diffusible
between membranes, and therefore must be produced in the
vicinity of the nucleus to regulate nuclear signaling proteins.
Here we show that PLCε is important for agonist-dependent
regulation of both nuclear Ca2+ release and PKD activation.
PLCε scaffolded at the NE is required to generate perinuclear
DAG important for nuclear PKD activation, but surprisingly, the
substrate for this reaction is in the uniquely localized perinuclear
Golgi apparatus. PKD is recruited to the Golgi apparatus in
a DAG-dependent manner in other cell types where it is involved
in lipid and vesicle trafficking (Campelo and Malhotra, 2012).
PLC, PKD, and ARF are critical regulators of Golgi fission
involved in the transport of cargo to the PM. Here, with the
unique architecture of the Golgi apparatus in cardiac myocytesand the perinuclear scaffolding of PLCε by mAKAP, the process
of PI hydrolysis and DAG generation appears to have been co-
opted to recruit and activate PKD in the vicinity of the nucleus,
where it can regulate nuclear gene expression.
Although we and others have shown that PI4P is a substrate
for mammalian PLC isoforms, including PLCε, in vitro (Fig-
ure S5B), PI4P has not been shown to be a native physiological
substrate for anymammalian PLC in cells. Thus, we demonstrate
here that PI4P hydrolysis is a physiologically relevant PLC reac-
tion that likely performs a widespread function in cell biology.
PI4P has generally been thought to function primarily as a
precursor to replace PIP2 as it is depleted by receptor-stimulated
PIP2 hydrolysis. Recently however, it has been shown that deple-
tion of PI4P does not significantly alter the level of PIP2 in cells,
nor does it affect acute receptor-stimulated PIP2 hydrolysis, indi-
cating that PI4P has functional roles other than simply serving as
a PIP2 precursor (Hammond et al., 2012).
We also show that PLCε is involved in regulation of ET-1-
dependent nuclear Ca2+ elevation. Previous studies have indi-
cated that local Ca2+ signaling at the nucleus is IP3 receptor
dependent and regulates HDAC nuclear export via activation
of CamKII (Wu et al., 2006). The source of IP3 was undefined in
these experiments but has been suggested to diffuse from the
PM. Hydrolysis of PI4P by PLC activity would generate DAG
and inositol 1,4-bisphosphate (IP2) and thus would not be a rele-
vant reaction for local IP3-dependent Ca
2+ release because IP2
does not regulate Ca2+ release through IP3 receptors. Thus the
role of PI4P hydrolysis by mAKAP-scaffolded PLCε at the Golgi
appears to be DAG generation for PKD activation. We propose
that a different pool of PLCε, perhaps at the PM in cooperation
with PLCb, generates IP3 from PIP2, which can diffuse to the
nucleus and release Ca2+ via IP3 receptors in the nucleus. Over-
all, our model is that PLCε is located in different subcellular com-
partments, allowing for regulation of hypertrophy and CICR via
different mechanisms.
In conclusion, we have discovered a novel integrator of
hypertrophic signals in the heart, PLCε, whose scaffolding at
the NE to generate DAG from the novel PLC substrate PI4P
in the perinuclear Golgi apparatus is critical for this function.
This suggests that PLCε catalytic activity could be a novel target
for heart failure. On the other hand, PLCε is found in many cell
types and has multiple functions (Smrcka et al., 2012). Global
deletion of PLCε increases the propensity for heart failure
(Wang et al., 2005). mAKAP has a more restricted distribution
and thus so does the PLCε-mAKAP complex (Kapiloff et al.,
1999). A more targeted strategy for treatment of heart failure
could involve developing reagents that interfere with PLCε scaf-
folding to mAKAP.
EXPERIMENTAL PROCEDURES
See the Extended Experimental Procedures for detailed methodology.
Cardiomyocyte-Specific Deletion of PLCε and Induction and
Analysis of Hypertrophy
PLCεflox/flox Cre+ and PLCεflox/flox Cre mice were generated as described in
the Extended Experimental Procedures. At 30 days after birth, mice were in-
jected intraperitoneally (i.p.) three times on consecutive days with 40 mg/kg
tamoxifen to excise exon 6 of the PLCe1 gene.Cell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc. 225
TAC
Two- to three-month-old tamoxifen (30–60 days after tamoxifen injection) in-
jected male PLCε WT (PLCεflox/flox Cre) and cardiac KO (PLCεflox/flox Cre+)
mice were subjected to TAC or sham operation (opening and closing chest
without aortic banding). Mice were anesthetized with isoflurane anesthesia
(2% inhaled) and intubated. Essentially as described by ourselves and others,
a transaortic constriction was produced (Ram et al., 2011; Rockman et al.,
1991).
Echocardiography
Transthoracic 2D andM-mode echocardiography analysis was used to assess
heart function after 4 weeks of TAC in mice under minimal isoflorane anes-
thesia with similar heart rates across animals using a Visualsonics Vevo
2100 echocardiography system (Visualsonics, Toronto, ON), using methods
as we have recently described (Ram et al., 2011).
Morphological Assessment of Hypertrophy
After 6 weeks of TAC, mice were euthanized, and hearts were harvested. Heart
and tibias were dissected. Heart weight and TL were measured. For histolog-
ical analysis, hearts were perfused and fixed with 10% formalin.
Isolation, Culture, Adenoviral Infection, siRNA Treatment, and
Hypertrophy Analysis of NRVMs
Isolation of NRVMs, adenoviral-mediated siRNA of PLCε, hypertrophy induc-
tion, and analysis were as previously described (Zhang et al., 2011).
Imaging of Phosphoinositide and DAG Reporters
Cells were imaged 24–48 hr after transfection with the appropriate plasmid at
1–2 mg. Transfection efficiency was approximately 5%. Fluorescent cells were
identified and imaged by confocal microscopy. During imaging and cpTOME,
ET-1, BFA, and PAO treatments, cells were in culture medium containing
serum. EGFP: excitation 488 nm, emission 510 nm; YFP: excitation 515 nm,
emission 527 nm; mCherry and mRFP: excitation 559 nm, emission 618 nm;
CFP: excitation 440, emission 476; DAPI and Hoeschst stains: excitation
405 nm, emission 461 nm.
Ca2+ Imaging
NRVMs were cultured on laminin (25 mg/ml; Invitrogen) coated coverslips. For
epifluorescent Ca2+ imaging, myocytes were loaded with Fura-2AM (2 mM) in
imaging buffer (HBSS containing in mM: 5.5 glucose, 0.56 MgCl2, 4.7 KCL, 1
Na2HPO4, 10 HEPES, 1.2 CaCl2, pH 7.4). One hundred micromolar ryanodine
was loaded in conjunction with Fura-2 dye for the ryanodine receptor block
experiments. For measurement of nuclear Ca2+ by two-photon microscopy,
myocytes were loaded with Fluo-4AM (2 mM) in imaging buffer. Fluo-4: excita-
tion 820 nm, emission 520 nm.
nDKAR FRET
NRVMs were transduced with an nDKAR-expressing adenovirus. Transduced
cells were identified with CFP excitation and emission. FRET was determined
as the ratio of YFP emission at 535 nm to CFP emission at 480 nm after CFP
excitation at 440 nm.
Measurement of PI4P Mass
PI4P was extracted from either vehicle- or cpTOME-treated myocytes (1 hr)
using a MeOH, CHCl3, HCl extraction protocol (Gray et al., 2003). The extract
was spotted onto a nitrocellulose filter, and PI4P was detected using a PI4P
protein lipid overlay assay according to the manufacturer’s instructions
(Echelon Biosciences Inc.) (Dowler et al., 2002).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two movies and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.02.047.226 Cell 153, 216–227, March 28, 2013 ª2013 Elsevier Inc.ACKNOWLEDGMENTS
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